ONE-P TMS First Responders (ONE-P_FR)
One-day rTMS + D-cycloserine to Treat PTSD in First Responders
研究概览
地位
详细说明
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Amanda Ding, BSc
- 电话号码:(604)-822-7308
- 邮箱:ninet.lab@ubc.ca
学习地点
-
-
British Columbia
-
Vancouver、British Columbia、加拿大、V6T 2A1
- Non-Invasive Neurostimulation Therapies Centre, University of British Columbia
-
接触:
- Amanda Ding
- 电话号码:(604)-822-7308
- 邮箱:ninet.lab@ubc.ca
-
首席研究员:
- Fidel Vila-Rodriguez
-
-
参与标准
资格标准
适合学习的年龄
- 成人
接受健康志愿者
描述
Inclusion Criteria:
- are outpatients between the ages of 19-60;
- are voluntary and competent to consent;
- are first responders (active, on leave or retired);
- have DSM-5 diagnosis of PTSD with a CAPS for DSM-5 (CAPS-5) score ≥ 25;
- 17-item Hamilton Depression Rating Scale score ≤ 23;
- have had no increase or initiation of any psychotropic medication in the 4 weeks prior to screening;
- if participating in psychotherapy, must have been in stable treatment for at least 1 month prior to entry into the study, with no anticipation of change in the frequency of therapeutic sessions, or the therapeutic focus over the duration of the study;
- able to adhere to the treatment schedule;
- Pass the TMS adult safety screening (TASS) questionnaire, and the MRI safety screening.
Exclusion Criteria:
- have a Severe Substance Use Disorder (except tobacco) within the last three (3) months;
- have a concomitant major unstable medical illness, cardiac pacemaker or implanted medication pump;
- have active suicidal intent;
- are pregnant;
- have a lifetime MINI diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or current psychotic symptoms;
- have a MINI diagnosis of OCD, or mood disorder that is assessed by a study investigator to be primary and causing greater impairment than PTSD;
- have a diagnosis of any personality disorder, assessed by a study investigator to be primary and causing greater impairment than MDD;
- have failed a course of ECT in the current episode or previous episode;
- have received rTMS for any previous indication;
- have any significant neurological disorder, history of seizure disorder (except those therapeutically induced by ECT), or any significant head trauma with clear radiological evidence of cerebrovascular injury on imaging;
- have an intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed;
- clinically significant laboratory abnormality, in the opinion of the one of the principal investigators or study physicians (including but not limited to abnormal blood urea nitrogen (BUN), creatinine, estimated glomerular filtration rate (eGFR));
- currently take more than lorazepam 2 mg daily (or equivalent) or any dose of an anticonvulsant due to the potential to limit rTMS efficacy;
- currently take dicumarol, gingko biloba, isoniazid, ethionamide, fluphenazine, metrizamide, tramadol, warfarin due to potential interactions with D-Cycloserine;
- planned vaccination with Bacille Calmette-Guérin, cholera or typhoid or planned imaging procedure with an injectable die, within one week following the treatment days, due to potential interactions with DCS.
- allergy to DCS
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:active aiTBS plus DCS
|
Participants randomized to the active treatment arm will receive DCS 125 mg orally, administered as one capsule around one hour before active aiTBS treatment.
rTMS will employ the MagPro X100/R30 stimulator (MagVenture, Farum, Denmark) equipped with the B70 coil. A scalp heuristic will be used to localize the treatment site over the right DLPFC by modifying the BeamF3 method to the contralateral side. We have previously reported good congruency between the BeamF3 heuristic method and MRI-guided neuronavigation. Prior to the first treatment, each subject's resting motor threshold (RMT) will first be determined according to published methods. Patients will receive 3 minutes of iTBS every 30 minutes for a total of 15 session over two separate days three weeks apart day of treatment using the following parameters: 50 Hz triplet bursts, 5 bursts per second, 2 s on and 8 s off for 20 trains of 600 pulses, preceded by an introductory 3-train acclimatization titration, at an intensity of 80% of the RMT. The treatment protocol will be repeated 3 weeks after the initial treatment day. |
|
安慰剂比较:active aiTBS plus placebo DCS
|
rTMS will employ the MagPro X100/R30 stimulator (MagVenture, Farum, Denmark) equipped with the B70 coil. A scalp heuristic will be used to localize the treatment site over the right DLPFC by modifying the BeamF3 method to the contralateral side. We have previously reported good congruency between the BeamF3 heuristic method and MRI-guided neuronavigation. Prior to the first treatment, each subject's resting motor threshold (RMT) will first be determined according to published methods. Patients will receive 3 minutes of iTBS every 30 minutes for a total of 15 session over two separate days three weeks apart day of treatment using the following parameters: 50 Hz triplet bursts, 5 bursts per second, 2 s on and 8 s off for 20 trains of 600 pulses, preceded by an introductory 3-train acclimatization titration, at an intensity of 80% of the RMT. The treatment protocol will be repeated 3 weeks after the initial treatment day.
Participants randomized to the placebo arm will receive one matched placebo capsule administered orally at the same time point and according to the same procedures as the active investigational product.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Feasibility of one-day iTBS+DCS: Enrolment
大体时间:2 years
|
Enrollment rate: participants enrolled ÷ enrolment target by the end of 1.5 years will be ≥ 70% of the enrollment targe
|
2 years
|
|
Feasibility: Adherence
大体时间:2 years
|
Proportion of randomized participants receiving ≥80% of scheduled iTBS sessions, defined as ≥24 session
|
2 years
|
|
Feasibility: dropout rates
大体时间:2 years
|
Percentage of dropout rates attributable to the intervention will be ≤ 10%
|
2 years
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Treatment group differences in change from baseline to 3-weeks post-treatment on the Clinician-Administered Posttraumatic Stress Disorder Scale for DSM 5 (CAPS-5) Total Severity Score
大体时间:3 weeks
|
Exploratory efficacy outcome: change in Clinician-Administered PTSD Scale for DSM 5 (CAPS-5).
Total Severity Score (20 item sum, range 0-80, higher score=greater severity) in change from baseline to 3-weeks after the intervention
|
3 weeks
|
|
Treatment group differences in change from baseline to 6-weeks post-treatment on the Clinician-Administered Posttraumatic Stress Disorder Scale for DSM 5 (CAPS-5) Total Severity Score
大体时间:6 weeks
|
Exploratory efficacy outcome: change in Clinician-Administered PTSD Scale for DSM 5 (CAPS-5).
Total Severity Score (20-item sum, range 0-80, higher score=greater severity) in change from baseline to 6-weeks after the intervention.
Weathers, FW, Blake, DD, Schnurr, PP, Kaloupek, DG, Marx, BP, & Keane, TM.
The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5).
www.ptsd.va.gov:
National Center for PTSD, 2013
|
6 weeks
|
合作者和调查者
调查人员
- 首席研究员:Fidel Vila-Rodriguez, M.D., PhD, FRCPC, DFAPA、University of British Columbia
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.